Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  etoposide
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 1680 for your search:
Start Over
Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 15 to 65
Sponsor: Other
Protocol IDs: GMALL03, NCT00199004
PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation
Phase: Phase IV
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20050100, NCT00352703
Treatment of Acute Myeloblastic Leukemia in Younger Patients
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 65 and under
Sponsor: Other
Protocol IDs: AML99<=65 años, NCT00390715
Oral Zinc Therapy for the Prevention of Mucositis
Phase: Phase IV
Type: Supportive care, Treatment
Status: Completed
Age: 18 to 70
Sponsor: Other
Protocol IDs: SHEBA-06-4196-MKM-CTIL, NCT00449592
German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 15 to 65
Sponsor: Other
Protocol IDs: GMALL04, NCT00199017
LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: Any age
Sponsor: Other
Protocol IDs: PETHEMA-LAM07, NCT01041040
Intensified Conditioning Regimen With High-Dose-Etoposide for Allo-HSCT for Adult Acute Lymphoblastic Leukemia
Phase: Phase IV
Type: Treatment
Status: Closed
Age: 16 to 65
Sponsor: Other
Protocol IDs: HDE-ALL-2011, NCT01457040
Phase II/III Randomized Study of Monoclonal Antibody HuM195 As Maintenance Therapy in Elderly Patients with Acute Myeloid Leukemia in Complete Remission Following Chemotherapy (Summary Last Modified 12/98)
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 60 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PDL-3-251, MSKCC-93131, NCI-V94-0469
Combination Chemotherapy in Treating Men With Germ Cell Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 16 to 50
Sponsor: Other
Protocol IDs: EORTC-30983, NCT00003643
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 4 to 70
Sponsor: Other
Protocol IDs: CDR0000066968, RP 98-15, RPCI-RP-9815, NCI-V99-1527, NCT00003816
Phase II/III cis-Platinum in 2-Drug and 3-Drug Combinations with VP-16 and DAVA for Advanced non-Oat Cell Carcinoma of the Lung
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: no age specified
Sponsor:
Protocol IDs: MDA-DT-8075, NCI-D81-043-098
Phase II/III Chemotherapy with CAMP (CTX/ADR/MTX/PCB) vs VP-16/DAVA/CACP vs VP-16/CACP vs DAVA/CACP for Stage III Metastatic non-Small Cell Bronchogenic Carcinoma
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: under 70
Sponsor:
Protocol IDs: UCCRC-3248, NCI-D81-014-080
Phase II/III Combination Chemotherapy with AMSA/AZC or AMSA/VP-16 for Acute Nonlymphocytic Leukemia Refractory to Standard Therapy
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: no age specified
Sponsor:
Protocol IDs: NCI-D82-013-686
Phase II/III Combination Chemotherapy with VP-16213/CTX/CACP in Patients with Stage II/III Testicular Carcinoma
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: over 15
Sponsor:
Protocol IDs: NCI-D82-043-188, MDA-IM-8104
Phase II/III Consolidation Chemotherapy with VP-16/AMSA/AZC Following Induction with DNM/ARA-C/TG for Adult Primary or Secondary Leukemia
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: NCI-D82-051-605
Phase II/III Randomized Evaluation of VP-16 at Three Dosage Levels for Recurrent or Refractory Small Cell Carcinoma of the Lung
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 65 and under
Sponsor:
Protocol IDs: SEG-LUN-81342R
Phase II/III L-PAM/PRED/VCR vs VP-16/PRED/ADR for Stage II/III Myeloma (Summary Last Modified 12/89)
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 20 and over
Sponsor:
Protocol IDs: SAFR-CT-MM-2
Phase II/III Pilot Combination Chemotherapy with ARA-C/VP-16/IPP plus Mesna plus Intrathecal MTX in Pediatric Patients with Recurrent Nonlymphoblastic Lymphoma (Summary Last Modified 07/90)
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: under 18
Sponsor: NCI
Protocol IDs: NCI-85-C-62, NCI-T85-0096N, T85-0096
Phase II/III Chemotherapy with CACP/VP-16 for Children with Recurrent Soft Tissue Sarcoma
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: under 21
Sponsor:
Protocol IDs: NCI-D81-039-767, CHP-436
Phase II/III Salvage Chemotherapy Using High-Dose CDDP/CTX/VP-16 Followed by Autologous Bone Marrow Transplant in Patients with Advanced Refractory Head and Neck Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: under 70
Sponsor:
Protocol IDs: UNMC-116, NCI-V85-0251
Start Over